Highlights
- EMG-guided Onabotulinum toxin A (50U) significantly reduced pain Visual Analogue Scale (VAS) scores at 3 months compared to placebo (p=0.008).
- Treatment led to sustained improvements in the Dermatology Life Quality Index (DLQI) at both 3-month and 6-month follow-ups.
- Significant enhancements were observed in sexual desire and sexual satisfaction according to the Female Sexual Function Index (FSFI).
- The study confirms that muscular dysfunction and hypertonicity are critical components of the pain profile in provoked vestibulodynia.
Background and Disease Burden
